tizanidine
FDA Approved
Description
Tizanidine is a centrally acting alpha-2 adrenergic agonist that reduces spasticity by increasing presynaptic inhibition of motor neurons. It is used in the management of spasticity associated with various neurological conditions including hereditary neuropathies and developmental disorders with motor dysfunction. The drug provides symptomatic relief for patients with muscle tone abnormalities.
Indications & Therapeutic Use
spasticity management, muscle tone disorders, neurological motor impairment
Global Availability (4 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
tizanidine
| Generic Name | tizanidine |
| Brands | 1 brand available |
| Active Ingredient | tizanidine hydrochloride |
| Drug Class | spasticity management |
| Manufacturer | Acorda Therapeutics |
| Dosage Forms | oral tablet 2mg, 4mg; oral capsule 2mg, 4mg, 6mg |
| Medical Code | M03BX02 |
| Orphan Status | No |
| Cold Chain | Not Required |
| Lead Time | 5 days |
| Reg. Status | FDA Approved |
| Countries | 4 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations5 Validated Nodes